10 Best Biotech Stocks Under $10 to Buy

4. Absci Corporation (NASDAQ:ABSI)

Number of Hedge Fund Holders: 39

Market Capitalization as of October 27: $1.42 Billion

Share Price as of October 27: $8.25

Absci Corporation has significantly outperformed the broader biotechnology sector in 2026, as investors increasingly recognize the potential of its artificial intelligence (AI)-powered drug discovery platform. A 180% plus year-to-date rally has propelled the stock higher.

Amid the blockbuster gains, Wall Street firms still see room for further upside, calling it one of the best biotech stocks under $10 to buy. KeyBanc reiterated a buy rating on the stock on October 16 and set a $20 price target, buoyed by progress in the company’s clinical pipeline.

JPMorgan had also raised its price target to $15 from $14, on October 12, while maintaining an overweight rating. The hike came amid heightened focus on the company’s generative AI-designed biologics platform. Is Absci still a Buy after explosive rally?

A key driver of investor interest is the company’s ABS-201 program, which targets potential treatments for conditions including endometriosis and hair loss. Absci has also reported encouraging interim Phase 1 results for ABS-201 in human trials as a treatment for durable hair growth. Explore how Absci is pursuing the hair loss opportunity.

Beyond pipeline development, investor sentiment improved after Eli Lilly participated in the company’s $100 million share offering. The investment provides additional capital to support the company’s drug discovery efforts and clinical development programs.

Positive early clinical data, strategic partnership, and enthusiasm for AI-driven drug discovery help explain why Wall Street firms are overly bullish on Absci’s long-term prospects.

3. Taysha Gene Therapies Inc. (NASDAQ:TSHA)

Number of Hedge Fund Holders: 41

Market Capitalization as of October 27: $1.38 Billion

Share Price as of October 27: $4.25

Taysha Gene Therapies Inc. (NASDAQ:TSHA) has retreated after a strong rally in 2025, with shares down about 19% in 2026. Despite the pullback, the company remains one of the best biotech stocks under $10 to buy, supported by encouraging clinical progress in its gene therapy pipeline, particularly TSHA-102.

On September 17, Wolfe Research reiterated an Outperform rating, citing potential of the company’s pipeline. The company has already delivered positive trial results for the investigational treatment for Rett Syndrome. Pivotal studies have shown that the candidate drug could become a disease-modifying treatment for patients who currently lack an approved therapy.

Rett syndrome has substantial unmet medical needs, creating substantial commercial opportunities. Therefore, Taysha is facing a tremendous revenue opportunity with a candidate drug demonstrating meaningful, durable benefits.

Additionally, the company remains in a strong financial position, having completed a $230 million follow-on offering in the second quarter. It also had about $455.4 million in cash and cash equivalents to support potential commercial production if TSHA-102 receives FDA approval.

Encouraging clinical progress, a potentially meaningful commercial opportunity, and a strengthened balance sheet underline why Taysha stands out as one of the top biotech stocks. Here’s how the stock stands out on valuation.